Perioperative Finotonlimab Plus Chemotherapy in Untreated Stage II HNSCC

Inclusion criteria

• . Age 18-75 years
• . Pathologically confirmed primary head and neck squamous cell carcinoma (excluding nasopharyngeal carcinoma)
• . Clinical stage II (8th edition TNM staging), no distant metastasis, primary tumor resectable
• . ECOG sccore 0-1
• . No prior radiotherapy, chemotherapy, immunotherapy, or biological therapy for the current head and neck tumor
• . Willing to undergo surgical treatment
• . No significant contraindications to immunotherapy, radiotherapy, or chemotherapy
• . Major organ function meets the following criteria: a) Hematologic: WBC ≥ 4.0 × 10⁹/L, ANC ≥ 1.5 × 10⁹/L, PLT ≥ 100 × 10⁹/L, Hb ≥ 90 g/L (no blood transfusion or blood products, no G-CSF or other hematopoietic growth factors within 14 days); b) Biochemistry: serum albumin ≥ 3.0 g/dL (30 g/L), TBIL ≤ 1.5 × ULN, ALT and AST ≤ 2.5 × ULN, BUN and CRE ≤ 1.5 × ULN or endogenous creatinine clearance ≥ 60 mL/min (Cockcroft-Gault formula); c) Adequate coagulation: defined as INR or PT ≤ 1.5 × ULN; if the subject is receiving anticoagulation therapy, PT within the intended therapeutic range of the anticoagulant is acceptable

Exclusion criteria